MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access EventPRNewsWire • 12/30/21
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety DisorderBenzinga • 12/22/21
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety DisorderPRNewsWire • 12/21/21
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring SystemPRNewsWire • 12/09/21
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study FindsBenzinga • 11/30/21
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybinPRNewsWire • 11/30/21
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSDBenzinga • 11/16/21
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical PipelinePRNewsWire • 11/15/21